Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Tavazzi, Luigi"" wg kryterium: Autor


Tytuł:
Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.
Autorzy:
Bouabdallaoui N; Montreal Heart Institute, Université de Montréal, 5000 Belanger Street, Montreal, H1T 1C8, Quebec, Canada.
O'Meara E; Montreal Heart Institute, Université de Montréal, 5000 Belanger Street, Montreal, H1T 1C8, Quebec, Canada.
Bernier V; Scientific and Medical Affairs, Servier Canada Inc., Laval, Quebec, Canada.
Komajda M; Department of Cardiology, Paris Saint Joseph Hospital, Paris, France.
Swedberg K; Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; National Heart and Lung Institute, Imperial College London, London, UK.
Tavazzi L; Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.
Borer JS; Howard Gilman and Schiavone Institutes, State University of New York Downstate Medical Center, New York, NY, USA.
Bohm M; Internal Medicine Clinic III, Saarland University Clinic, Saarland University, Homburg, Saar, Germany.
Ford I; Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.
Tardif JC; Montreal Heart Institute, Université de Montréal, 5000 Belanger Street, Montreal, H1T 1C8, Quebec, Canada.
Pokaż więcej
Źródło:
ESC heart failure [ESC Heart Fail] 2019 Dec; Vol. 6 (6), pp. 1199-1207. Date of Electronic Publication: 2019 Oct 08.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Cardiovascular Agents/*therapeutic use
Heart Failure/*drug therapy
Ivabradine/*therapeutic use
Aged ; Female ; Heart Failure/physiopathology ; Heart Rate ; Humans ; Male ; Middle Aged ; Stroke Volume
Czasopismo naukowe
Tytuł:
Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT.
Autorzy:
Böhm M; Internal Medicine Clinic III, Saarland University Clinic, Saarland University, Homburg, Saar, Germany.
Komajda M; Department of Cardiology, Paris Saint Joseph Hospital, Paris, France.
Borer JS; Howard Gilman and Schiavone Institutes, State University of New York Downstate Medical Center, New York, NY, USA.
Ford I; Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.
Maack C; Internal Medicine Clinic III, Saarland University Clinic, Saarland University, Homburg, Saar, Germany.; Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany.
Tavazzi L; Maria Cecilia Hospital, GVM Care and Research, Ettore Sansavini Health Science Foundation, Cotignola, Italy.
Moyne A; Department of Methodology and Valorisation of Data, International Research Institute Servier, Suresnes, France.
Swedberg K; Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; National Heart and Lung Institute, Imperial College London, London, UK.
Pokaż więcej
Corporate Authors:
SHIFT Investigators
Źródło:
European journal of heart failure [Eur J Heart Fail] 2018 Feb; Vol. 20 (2), pp. 373-381. Date of Electronic Publication: 2017 Oct 12.
Typ publikacji:
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Heart Failure, Systolic/*drug therapy
Heart Rate/*drug effects
Ivabradine/*administration & dosage
Stroke Volume/*physiology
Ventricular Function, Left/*drug effects
Cardiovascular Agents/administration & dosage ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Follow-Up Studies ; Heart Failure, Systolic/physiopathology ; Hospitalization/trends ; Humans ; Male ; Middle Aged ; Stroke Volume/drug effects ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Time to benefit of heart rate reduction with ivabradine in patients with heart failure and reduced ejection fraction.
Autorzy:
Böhm, Michael
Abdin, Amr
Slawik, Jonathan
Mahfoud, Felix
Borer, Jeffrey
Ford, Ian
Swedberg, Karl
Tavazzi, Luigi
Batailler, Cécile
Komajda, Michel
Pokaż więcej
Temat:
HEART failure patients
HEART beat
VENTRICULAR ejection fraction
IVABRADINE
CARDIOVASCULAR disease related mortality
Źródło:
European Journal of Heart Failure; Aug2023, Vol. 25 Issue 8, p1429-1435, 7p, 1 Chart, 4 Graphs
Czasopismo naukowe
Tytuł:
Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT.
Autorzy:
Komajda, Michel
Tavazzi, Luigi
Swedberg, Karl
Böhm, Michael
Borer, Jeffrey S.
Moyne, Aurélie
Ford, Ian
Pokaż więcej
Źródło:
European Journal of Heart Failure. Sep2016, Vol. 18 Issue 9, p1182-1189. 8p. 1 Diagram, 2 Charts, 1 Graph.
Czasopismo naukowe
Tytuł:
Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial.
Autorzy:
Komajda, Michel
Tavazzi, Luigi
Francq, Bernard G.
Böhm, Michael
Borer, Jeffrey S.
Ford, Ian
Swedberg, Karl
Böhm, Michael (AUTHOR)
SHIFT Investigators (CORPORATE AUTHOR)
Pokaż więcej
Źródło:
European Journal of Heart Failure. Dec2015, Vol. 17 Issue 12, p1294-1301. 8p. 1 Diagram, 4 Charts, 1 Graph.
Czasopismo naukowe
Tytuł:
Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy.
Autorzy:
Böhm, Michael
Borer, Jeffrey S.
Camm, John
Ford, Ian
Lloyd, Suzanne M.
Komajda, Michel
Tavazzi, Luigi
Talajic, Mario
Lainscak, Mitja
Reil, Jan‐Christian
Ukena, Christian
Swedberg, Karl
Pokaż więcej
Temat:
HEART failure treatment
HEART beat
IVABRADINE
AMBULATORY electrocardiography
PATIENT monitoring
Źródło:
European Journal of Heart Failure; May2015, Vol. 17 Issue 5, p518-526, 9p, 2 Diagrams, 6 Charts
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies